Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

2009 ◽  
Vol 33 (8) ◽  
pp. 1079-1081 ◽  
Author(s):  
Salvatore Guastafierro ◽  
Umberto Falcone ◽  
Maria Celentano ◽  
Milena Coppola ◽  
Maria Giovanna Ferrara ◽  
...  
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Imatinib Mesylate ◽  
Myeloid Leukemia ◽  
Review Of The Literature

scholarly journals Leukemic arthritis and severe hypercalcemia in a man with chronic myeloid leukemia: a case report and review of the literature

2018 ◽  
Vol 12 (1) ◽  
Author(s):  
Pongprueth Rujirachun ◽  
Apichaya Junyavoraluk ◽  
Weerapat Owattanapanich ◽  
Voraparee Suvannarerg ◽  
Sirinart Sirinvaravong
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Review Of The Literature ◽  
Severe Hypercalcemia

Chronic Myeloid Leukemia as a Secondary Malignancy after Lymphoma in a Child. A Case Report and Review of the Literature

Onkologie ◽  
2012 ◽  
Vol 35 (11) ◽  
pp. 690-693 ◽  
Author(s):  
Kmira Zahra ◽  
Wafa Ben Fredj ◽  
Yosra Ben Youssef ◽  
Houneida Zaghouani ◽  
Imène Chebchoub ◽  
...  
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Secondary Malignancy ◽  
Review Of The Literature

Chronic myeloid leukemia with expression of ALL-type BCR/ABL transcript: a case-report and review of the literature

1999 ◽  
Vol 23 (9) ◽  
pp. 851-854 ◽  
Author(s):  
P Solves ◽  
P Bolufer ◽  
J.A López ◽  
E Barragán ◽  
L Bellod ◽  
...  
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Review Of The Literature

scholarly journals Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Bader Alharbi ◽  
Samer Alamri ◽  
Ahmed Mahdi ◽  
Siham Marghalani
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Fluid Retention ◽  
Review Of The Literature ◽  
Dermatology Clinic ◽  
Imatinib Resistant ◽  
Dasatinib Treatment ◽  
New Onset

Dasatinib is an oral second-generation multitarget tyrosine-kinase inhibitor (TKI) that is efficacious in treating imatinib-resistant chronic myeloid leukemia (CML) or intolerant cases. Noncutaneous adverse effects with dasatinib are well known in the literature, most commonly cytopenias and fluid retention, while pigmentary abnormalities have rarely been reported. We report the case of a 12-year-old male known case of CML, who presented to dermatology clinic approximately 2 years after initiating dasatinib treatment, with new-onset hypopigmentation of his upper limb, upper chest, and both knees of six months’ duration.

scholarly journals Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature

Transfusion ◽  
2017 ◽  
Vol 58 (2) ◽  
pp. 456-460 ◽  
Author(s):  
Elizabeth M. Staley ◽  
Sierra C. Simmons ◽  
Alexander Z. Feldman ◽  
Robin G. Lorenz ◽  
Marisa B. Marques ◽  
...  
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Review Of The Literature
Sign in / Sign up

Export Citation Format

Share Document